Javor Juraj, Bucová Mária, Ďurmanová Vladimíra, Radošinská Dominika, Párnická Zuzana, Čierny Daniel, Kurča Egon, Čopíková-Cudráková Daniela, Gmitterová Karin, Shawkatová Ivana
Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava and University Hospital Martin, 036 59 Martin, Slovakia.
Life (Basel). 2022 Jul 21;12(7):1094. doi: 10.3390/life12071094.
Polymorphisms in genes encoding receptors that modulate the activity of microglia and macrophages are attractive candidates for participation in genetic susceptibility to multiple sclerosis (MS). The aims of the study were to (1) investigate the association between Alzheimer’s disease-linked variant rs3865444:C>A in the CD33 gene and MS risk, (2) assess the effect of the strongest MS risk allele HLA-DRB115:01 on this association, and (3) analyze the correlation of rs3865444 with selected clinical phenotypes, i.e., age of onset and disease severity. CD33 rs3865444 was genotyped in a cohort of 579 patients and 1145 controls and its association with MS risk and clinical phenotypes was analyzed by logistic and linear regression analysis, respectively. Statistical evaluation revealed that rs3865444 reduces the risk of MS in the HLA-DRB115:01-positive subpopulation but not in the cohort negative for HLA-DRB115:01. A significant antagonistic epistasis between rs3865444 A and HLA-DRB115:01 alleles in the context of MS risk was detected by the interaction synergy factor analysis. Comparison of allele and genotype distribution between relapsing-remitting MS, secondary progressive MS, and control groups revealed that rs3865444 C to A substitution may also be associated with a decreased risk of transition of MS to its secondary progressive form, irrespective of the HLA-DRB1*15:01 carrier status. On the other hand, no correlation could be found between rs3865444 and the age of disease onset or MS severity score. Future studies are required to shed more light on the role of CD33 in MS pathogenesis.
编码调节小胶质细胞和巨噬细胞活性的受体的基因多态性,是参与多发性硬化症(MS)遗传易感性的有吸引力的候选因素。本研究的目的是:(1)研究CD33基因中与阿尔茨海默病相关的变体rs3865444:C>A与MS风险之间的关联;(2)评估最强的MS风险等位基因HLA-DRB115:01对这种关联的影响;(3)分析rs3865444与选定的临床表型(即发病年龄和疾病严重程度)之间的相关性。对579例患者和1145例对照的队列进行CD33 rs3865444基因分型,并分别通过逻辑回归和线性回归分析其与MS风险和临床表型的关联。统计评估显示,rs3865444降低了HLA-DRB115:01阳性亚组中MS的风险,但在HLA-DRB115:01阴性的队列中未降低。通过相互作用协同因子分析,在MS风险背景下检测到rs3865444 A和HLA-DRB115:01等位基因之间存在显著的拮抗上位性。复发缓解型MS、继发进展型MS和对照组之间等位基因和基因型分布的比较显示,无论HLA-DRB1*15:01携带者状态如何,rs3865444从C到A的替换也可能与MS转变为继发进展型的风险降低有关。另一方面,未发现rs3865444与疾病发病年龄或MS严重程度评分之间存在相关性。未来需要更多研究来阐明CD33在MS发病机制中的作用。